Roivant Sciences Ltd. (ROIV)
NEUTRALFundamental
34
Preço
$36.47
Capitalização de Mercado
$26.29B
Parte 1 · Quanto vale a empresa
Visão Geral
Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully human monoclonal antibody targeting FcRn in development across several IgG-mediated autoimmune indications; mosliciguat, an inhaled sGC activator in development for pulmonary hypertension associated with interstitial lung disease; neonatal fragment crystallizable receptor for the treatment of graves' disease, difficult-to-treat rheumatoid arthritis, sjögren's disease, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and cutaneous lupus erythematosus indications; batoclimab, a fully human monoclonal antibody for the treatment of thyroid eye disease; and brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis, non-infectious uveitis, cutaneous sarcoidosis, and other immune-mediated diseases. The company's lead program consists of mosliciguat, an inhaled sGC activator for the treatment of pulmonary hypertension associated with interstitial lung disease and other cardiopulmonary diseases. In addition, the company offers delivery platforms comprising a lipid nanoparticle (LNP) platform and a ligand conjugate platform. Roivant Sciences Ltd. was founded in 2014 and is based in London, United Kingdom.
No editorial profile for this company yet
Direct competitors
Who this company fights with for the same customers
No editorial profile for this company yet
No competitor list for this company yet.
Balanço & Liquidez
Receita
$8M
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$-266M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$-759M
Capital Próprio Total
$4.53B
Passivo Total
$416M
Rácio de Liquidez
16.72
Cobertura de Juros
-
Dívida/EBITDA
-
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$41.82
Preço Atual
$36.47
Margem de Segurança
+12.8%
Intervalo de Valor Justo
$39.73 - $43.91
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
-
ROE
-6.6%
Rácio P/B
6.21
P/FCF
-
Margem Bruta
-
ROIC
-9.4%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
-9.4%
WACC
10.5%
ROIC − WACC
-19.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (7)
- EPS shows upward trend
- Price CAGR 23.63%
- Debt/Equity ratio
- Current Ratio
- Low reliance on intangibles
- Analyst Consensus 89% Buy
- Share Dilution -22.5%
Reprovado (11)
- ROIC -9.4%
- P/B Ratio 6.21
- Operating Margin -7914.8%
- Positive Free Cash Flow
- Return on Tangible Assets
- DCF valuation (Unknown)
- ROE -6.1%
- Revenue Growth 5Y -19.1%
- Earnings Surprise avg -2.3%
- Net Margin Trend -3535.0% vs -2111.8%
- Piotroski F-Score 1/9
Indisponível (9)
- Gross Margin NaN%
- P/FCF NaN
- Dividend Payout NaN%
- CapEx intensity
- Interest Coverage
- Debt/EBITDA
- Price below Graham Number
- PEG Ratio (need PE > 0 and growth > 0)
- Earnings Quality (OCF/Net Income)
Piotroski F-Score
Preocupações financeiras graves
Qualidade dos Resultados
Baixa qualidade: investigar a contabilidade
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Matthew Gline | CEO & Director | 41 |
| Dr. Eric Venker M.D., Pharm.D. | President & CEO of Immunovant | 38 |
| Dr. Mayukh Sukhatme M.D. | President, Chief Investment Officer & Director | 49 |
| Dr. Frank M. Torti M.B.A., M.D. | President & Vant Chair | 46 |
| Mr. Richard Pulik | Chief Financial Officer | 45 |
| Ms. Jennifer Humes | Chief Accounting Officer | 44 |
| Mr. Ian Rosenblum | Chief Information Officer | - |
| Mr. Sam Kaplan | General Counsel | - |
| Ms. Kelly Graff | Head of People | - |
| Mr. Alex Gasner | Executive Vice President of Roivant Health | - |
Risco de Auditoria
5
Risco do Conselho
7
Risco de Remuneração
10
Risco dos Direitos dos Acionistas
4
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for ROIV, sourced from Markets Gazette.
- 19d agoPOSITIVERoivant Expects FDA to Approve First Major Drug
Roivant Sciences Ltd. is anticipating FDA approval for its novel drug targeting a severe skin condition, with a market launch projected for September. CEO Matt Gline expressed optimism about the drug's potential. This development represents a significant milestone for Roivant, potentially unlocking a new revenue stream and validating its research and development pipeline. Investors will be closely watching the official FDA decision, as approval could lead to substantial growth and market share gains in the dermatology sector.
via Markets Gazette